Prothena Corporation plc (PRTA)
NASDAQ: PRTA · Real-Time Price · USD
8.05
+0.51 (6.76%)
At close: Aug 13, 2025, 4:00 PM
8.05
0.00 (0.00%)
After-hours: Aug 13, 2025, 6:39 PM EDT
Prothena Corporation Revenue
Prothena Corporation had revenue of $4.42M in the quarter ending June 30, 2025, a decrease of -96.65%. This brings the company's revenue in the last twelve months to $10.34M, down -95.24% year-over-year. In the year 2024, Prothena Corporation had annual revenue of $135.16M with 47.92% growth.
Revenue (ttm)
$10.34M
Revenue Growth
-95.24%
P/S Ratio
39.24
Revenue / Employee
$63,442
Employees
163
Market Cap
433.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 135.16M | 43.79M | 47.92% |
Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PRTA News
- 7 days ago - Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 9 days ago - Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 16 days ago - Prothena to Report Second Quarter 2025 Financial Results on August 4 - Business Wire
- 2 months ago - Prothena Announces Corporate Restructuring - Business Wire
- 2 months ago - Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease - Business Wire
- 2 months ago - Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga
- 2 months ago - Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint - Business Wire
- 3 months ago - Top 3 Health Care Stocks That Are Preparing To Pump This Quarter - Benzinga